Regulus Therapeutics this week said that it has completed its previously announced public stock offering of roughly 5.1 million shares at $9.50 a share. The company also said that the overallotment option to buy an additional 675,000 shares has been fully exercised by the offering’s underwriters.
Gross proceeds of the offering were $49.2 million.